iNKT Cells Retain Full Capacity for Activation and Tumor Cell Killing Throughout Manufacturing



Allogeneic cell product batch production also provides the opportunity for more rigorous quality control and release of consistent cell-product by producing large numbers of doses per manufacturing run for both non-engineered and engineered products. Using healthy donor cells as the starting material eliminates the risk that such cells will be exhausted, or damaged, from prior chemotherapy or hematopoietic stem cell transplantation. Advance manufacturing also reduces the risk of batch failure, as every manufacturing run of cells can be more rigorously validated prior to release.